R&D
Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...
Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (